Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
Views & Analysis Value for money of Health Technology Assessment Health Technology Assessment (HTA), despite the many definitions in use, has become almost synonymous with value for money (VfM). But just what is the value for money of HTA itself?
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
